- Home
- KYTX
as 05-20-2024 2:32pm EST
Kyverna Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on developing cell therapies for patients suffering from autoimmune diseases. Its product KYV-101, is an autologous CD19 CAR T-cell product candidate made from an underlying chimeric antigen receptor, or CAR. It is also developing KYV-201, an allogeneic therapy containing the same CAR as KYV-101, to develop it in multiple autoimmune diseases.
| Founded: | 2018 | Country: | Canada |
| Employees: | N/A | City: | EMERYVILLE |
| Market Cap: | 629.5M | IPO Year: | 2024 |
| Target Price: | $39.50 | AVG Volume (30 days): | 392.3K |
| Analyst Decision: | Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.76 | EPS Growth: | N/A |
| 52 Week Low/High: | $12.26 - $30.60 | Next Earning Date: | 05-14-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | 33.33% |
Share on Social Networks:
Stock Insider Trading Activity of KYVERNA THERAPEUTICS INC (KYTX)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Vida Ventures, LLC | KYTX | 10% Owner | Feb 12 '24 | Buy | $22.00 | 252,553 | $5,556,166.00 | 252,553 | SEC Form 4 |
| Vida Ventures, LLC | KYTX | 10% Owner | Feb 12 '24 | Buy | $22.00 | 583 | $12,826.00 | 583 | SEC Form 4 |
| Northpond Ventures III GP, LLC | KYTX | Feb 12 '24 | Buy | $22.00 | 450,000 | $9,900,000.00 | 450,000 | SEC Form 4 | |
| GILEAD SCIENCES, INC. | KYTX | 10% Owner | Feb 12 '24 | Buy | $22.00 | 910,000 | $20,020,000.00 | 4,126,119 | SEC Form 4 |
Latest KYVERNA THERAPEUTICS INC News
KYTX Breaking Stock News: Dive into KYTX Ticker-Specific Updates for Smart Investing
PR Newswire
6 days ago
Kyverna Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results
PR Newswire
a month ago
Kyverna Therapeutics to attend the 2024 American Academy of Neurology (AAN) Annual Meeting in Denver, CO, With Data on KYV-101 in the Treatment of Patients with Neurological Autoimmune Diseases
PR Newswire
2 months ago
First-in-Disease Use of Kyverna Therapeutics' KYV-101 in Patients With Progressive Multiple Sclerosis Published in Med
PR Newswire
2 months ago
Kyverna Therapeutics Provides Business Update and Reports Full Year 2023 Financial Results
The Wall Street Journal
2 months ago
Why That Hot Biotech IPO Could Be a Winner
PR Newswire
2 months ago
Kyverna Therapeutics and Stanford University Agree to Evaluate KYV-101 in Patients with Non-Relapsing and Progressive Forms of Multiple Sclerosis
Yahoo Finance Video
2 months ago
How Kyverna is positioned for success on autoimmune therapy: CEO
PR Newswire
3 months ago